The linkurl:Geron Corporation;http://www.geron.com/ linkurl:announced on Tuesday;http://www.geron.com/media/pressview.aspx?id=1187 (August 18) that its stem cell study of spinal cord injury -- the first-ever clinical trial using human embryonic stem cell (hESC)-based therapy -- has been put on hold by the linkurl:US Food and Drug Administration;http://www.fda.gov/ (FDA) pending the review of some newly submitted animal data. Human embryonic stem cellsImage: Wikimedia commons, Nissim Benvenisty
View Full Profile
Learn about our Editorial Policies.
 |
Image: Wikimedia commons, Nissim Benvenisty |
Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.
View Full Profile
The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.
View this Issue
In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.
In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.
In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.
In this webinar, Andre Mueller will discuss how scientists characterize therapeutic proteins in different formulations and spot the effects of excipients on protein stability.
The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.
Partnership unites AI and single cell technology to map immune dysfunction and improve drug discovery and development outcomes
Designed to balance ease of use, cost efficiency, and reproducible data, which are critical requirements for successful high-throughput screening campaigns
Automated Twist NGS library preparation workflows available on SPT Labtech’s firefly platform via the firefly cloud
